Written and edited by Abel B. Daartey, PharmD

• Every new medicine carries a hidden story of failed experiments, patient participation, and years of scientific persistence.
• Daraxonrasib, approved in 2026 for certain patients with metastatic pancreatic adenocarcinoma, shows how a difficult cancer target can slowly become druggable.
• The story is not only about one drug. It is about why basic science, clinical trials, and patience matter in medicine.

The public usually sees the final headline: “FDA approves new drug.”

But behind that headline are years of basic science, failed compounds, improved chemistry, better structural biology, patient participation in clinical trials, and researchers who refused to accept that a target was permanently impossible.

That is the part of medicine we do not talk about enough.

By the time a drug receives approval, it already has a long history. It has passed through questions, failures, corrections, redesigns, safety checks, and human trials. The approval is not the beginning of the story. It is the point where the story becomes visible to the public.

A good recent example is daraxonrasib, sold as Rasonque.

In August 2026, the FDA approved daraxonrasib for certain adults with metastatic pancreatic adenocarcinoma. This matters because pancreatic cancer remains one of the most difficult cancers to treat. It is often diagnosed late, has aggressive biology, and still carries poor survival outcomes compared with many other cancers.[1,3,4]

But this approval is also important for another reason. Daraxonrasib goes after RAS, a signaling protein family that has challenged cancer researchers for decades.

One member of this family, KRAS, is one of the most frequently altered cancer genes across solid tumors.[2] In simple terms, RAS proteins behave like molecular switches inside the cell. When the cell needs a growth signal, the switch turns on. When the message has been delivered, it should turn off.

But in cancer, that switch can get stuck.

When RAS signaling stays active, cancer cells may keep receiving growth and survival messages even when they should slow down. That is one reason RAS has been such an important target in cancer biology.

The frustrating part is that scientists knew RAS was important long before they could drug it well.

For many years, RAS was often called “undruggable.” Not because researchers were not trying, but because the protein was difficult to target. It is small, smooth, and very good at holding tightly to the molecules that help it function. For drug developers, it did not present many easy places for a medicine to bind.

So for decades, RAS was like a locked door in cancer pharmacology. Everyone knew what was behind it, but opening it was another matter.

Then science kept pushing.

With better chemistry, improved structural biology, deeper knowledge of cancer signaling, and many years of trial and error, researchers began finding ways to target RAS-driven cancers more directly.

Daraxonrasib is part of that progress.

In the clinical trial that supported approval, patients who received daraxonrasib lived a median of 13.2 months, compared with 6.7 months for patients who received standard chemotherapy.[5,6]

That does not mean the drug is a cure. It does not mean every patient will respond the same way. But in metastatic pancreatic cancer, where options can be limited, that difference matters.

It means more time.

It means another option.

It means a target once described as almost impossible is no longer completely out of reach.

To me, this is one of the most beautiful parts of pharmacology. A drug is not just a chemical with a brand name. A drug is the result of many questions being asked carefully over many years.

What does this protein do?
How does it change in cancer?
Where can we interrupt the signal?
Can we block it without causing too much harm?
Can this idea survive the long journey from the lab bench to the patient?

Daraxonrasib also reminds us to be careful with the word “undruggable.”

Sometimes “undruggable” does not mean impossible. It only means science has not yet found the right angle, the right tool, or the right level of patience.

Still, this story should be told with balance.

Pancreatic cancer remains a serious disease. Many patients are still diagnosed late. Resistance can still emerge. Side effects still matter. Access and cost will also shape how much benefit patients can receive from this type of treatment.

So this is not a victory lap.

It is a meaningful step.

And meaningful steps matter in cancer research. They show that old problems can be reopened with new tools. They show that difficult targets can become possible targets. They show that years of basic science may one day become hope in the clinic.

Sometimes, the hardest targets are not impossible.

They are waiting for science to catch up.

Featured image generated with OpenAI for BreathPharma.

References

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
2. Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6:91. doi:10.1038/s41698-022-00334-z
3. Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014
4. American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html
5. U.S. Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
6. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. doi:10.1056/NEJMoa2605555